PT  - JOURNAL ARTICLE
AU  - Charles, Hannah
AU  - Thorley, Katie
AU  - Turner, Charlie
AU  - Bennet, Kirsty F.
AU  - Andrews, Nick
AU  - Bertran, Marta
AU  - Mandal, Sema
AU  - Amirthalingam, Gayatri
AU  - Ramsay, Mary E.
AU  - Mohammed, Hamish
AU  - Sinka, Katy
TI  - Post-peak mpox in England: epidemiology, reinfection, and vaccine effectiveness – data from 2023
AID  - 10.1101/2024.02.26.24303362
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.26.24303362
4099  - http://medrxiv.org/content/early/2024/02/28/2024.02.26.24303362.short
4100  - http://medrxiv.org/content/early/2024/02/28/2024.02.26.24303362.full
AB  - England, like other countries that experienced a large outbreak of emergent mpox in 2022, continued to record cases during 2023 at a low but steady frequency. Comprehensive national surveillance shows that cases continue to occur primarily among gay, bisexual and other men who have sex with men mostly in London. Of 137 cases in 2023, around half were acquired overseas, half were vaccinated, and one case of reinfection was reported. Eleven people required hospital care. High vaccination uptake, during 2022, has provided good coverage of those at higher risk of mpox. Using the screening method, vaccine effectiveness of one dose was estimated at 84%. None of the vaccinated cases in 2023 were hospitalised.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript